Despite the therapeutic potential of anti-PD-1 therapy, tumors that lack effective antigen presentation or adequate T cell infiltration remain largely unresponsive, underscoring the necessity for complementary strategies to modulate the immunosuppressive tumor environment (5). Here, PDCD1 is linked to neoplasm.